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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not peppermint 
oil reduces the symptoms and improves the quality of life in patients with irritable bowel 
syndrome (IBS). 
 
Study Design: Review of three randomized, double-blind, placebo controlled clinical trials were 
used in this review.  The articles were found on PubMed, and selected based on outcomes 
measured and relevance to the objective. 
 
Outcomes Measured: The outcomes measured were based on Quality of life and Reduction in 
Symptoms.  Quality of life was measured using the Persian translation of the SF-6 form for 
assessment of quality of life before and after treatment.  Reduction of Symptoms was measured 
using a mean symptom scores before and after the treatment. 
 
Results: The Merat, et al. study found a statistically significant improvement in reduction of 
symptoms including abdominal pain and discomfort, and show a statistically significant 
improvement in quality of life.  Cappello, et al. also found a statistically significant reduction in 
symptoms including abdominal pain, discomfort, bloating, diarrhea and constipation.  Alam, et 
al. also found a statistically significant reduction in symptoms especially abdominal pain, but did 
not see a statistically significant improvement in quality of life. 
 
Conclusions:  Based on these three randomized, double-blind, and placebo controlled clinical 
trials the efficacy of peppermint oil to treat irritable bowel syndrome is fairly conclusive as an 
effective treatment to reduce symptoms.  The populations studied in these studies were not large 
and lost a lot of patients to follow-up, which are factors that should be addressed in future studies 
 
Key Words: Irritable Bowel Syndrome, IBS, Peppermint Oil 
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Introduction 
 Irritable Bowel Syndrome (IBS) is a chronic disorder of the GI tract that affects a large 
population of people throughout the world.  It is a gastrointestinal syndrome characterized by 
chronic abdominal pain and altered bowel habits in the absence of any organic cause1.  These 
symptoms are not explicable by the presence of structural or biochemical abnormalities2.  It is 
characterized by abdominal discomfort or pain that has two of the following three features: 
relieved with defecation, onset associated with a change in frequency of stool, or onset 
associated with a change in form (appearance) of stool2.  IBS is further categorized into four 
different types3.  IBS with Constipation (IBS-C) is defined when the person’s stool is hard or 
lumpy most of the time, and occasional bowel movements with loose stools3.  IBS with diarrhea 
(IBS-D) is defined when the person’s stool is loose or watery most of the time and occasional 
bowel movements with hard stool3.  Mixed IBS (IBS-M) is defined as a mixture of IBS-D and 
IBS-C, specifically defined as a person with occasional hard bowel movements and occasional 
loose bowel movements3.  Unspecified IBS is defined as insufficient abnormality of stool 
consistency to meet criteria for the other types of IBS3.  There is no single pathophysiological 
marker of IBS4. 
Despite being a common condition throughout the world, IBS is a chronic troublesome 
condition that puts both patients and the healthcare system into heavy expenses as a result of 
significant impairment in health-related quality of life and work productivity5.  IBS is present in 
10% to 20% of adults in the US3.  Only about 15% of those affected actually seek medical 
attention3.  The health care cost of IBS in the US is estimated at $8 billion a year, and IBS is the 
most common cause for referral to gastroenterologists, up to 50% of referred patients3. 
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There is no definitive cure for IBS, only therapies to control symptoms.  The first-line 
treatment for all types of IBS is typically lifestyle and dietary modifications3.  The next line of 
treatment is pharmacologic treatment to control symptoms.  Some examples of pharmacologic 
treatment include, laxatives used for constipation predominantly, loperamide for diarrhea not 
controlled by diet, and antidiarrheals and antispasmodics are used for diarrhea predominant3.  
Other adjunct treatments for IBS include cognitive behavioral therapy or tricyclic 
antidepressants3. 
Since there is no definitive cure for IBS, various experimental treatments are undergoing 
research to become available to control symptoms of IBS.  One of those experimental treatments 
is peppermint oil.  The major component in Peppermint oil, is menthol5.  Menthol has relaxing 
effects on gastrointestinal smooth muscle by blocking Ca2+ channels in the gut, which may be 
useful in improving IBS symptoms5.  This systematic review evaluates three randomized control 
trials to determine the effectiveness of peppermint oil in reducing symptoms and improving 
quality of life for patients with IBS. 
Objective 
The objective of this selective EBM review is to determine whether or not peppermint oil 
reduces the symptoms and improves the quality of life in adult patients with irritable bowel 
syndrome (IBS).   
Methods 
 Criteria used for selection of studies for this systematic review is based on population 
studied, interventions, and the outcomes measured.  The populations studied in these articles 
were male and female adults that were diagnosed with IBS using the ROME II criteria.  These 
patients did not present with any other conditions or had any abnormal lab studies.  The 
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intervention was a dosage of peppermint oil compared to a visually matched placebo.  The 
studies measured outcomes using patient-oriented evidence that matters including reduction in 
symptoms and improvement in quality of life. 
 Research for this systematic review was obtained using PubMed to find double-blind, 
randomized controlled trials published in peer-reviewed journals within the last 10 years in the 
English language. The key words used in searches for these articles were “irritable bowel 
syndrome” and “peppermint oil”.  The articles selected during this search were based on their 
relevance to the objective in this systematic review.  This included studies where the participant 
groups of adult patients were greater than 18 years old diagnosed with IBS, and whether or not 
they evaluated the outcome of the treatment based on patient-oriented evidence that matters.  The 
exclusion criteria for this systematic review were scientific papers that included patients under 
the age of 18 years old, studies that were not randomized, double-blind, placebo controlled trials, 
and trials that measured treatment outcomes not based on patient-oriented evidence that matters.  
The statistics used by these articles analyzed the data using Chi-square, Mann-Whitney U and 
paired and unpaired t-tests.  The data from the articles was analyzed in the systematic review 
using p-values, Relative Risk Ratio, numbers needed to treat, numbers needed to harm and 
Confidence Interval using dichotomous and continuous data from the articles to analyze the 
efficacy of peppermint oil in reducing symptoms and improving quality of life in patients with 
IBS compared to a visually matched placebo. 
Outcomes Measured 
 The outcomes that were measured in these studies were reduction in symptoms and 
quality of life.  Merat et. al assessed quality of life in the participants using the Persian 
translation of the SF- 36 form for assessment of quality of life5.  The SF-36 form was a 
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questionnaire that was completed by the researchers when they visited the patients during 
treatment follow-up after 1 week and again after 4 weeks.  They also used a separate 
questionnaire filled out by the researchers to rate the intensity and frequency of each symptom 
that was experienced by the patient on a scale of 0-35.  The symptoms that were assessed 
included abdominal pain, abdominal discomfort, heart burn, nausea, vomiting, abdominal 
distention and bloating, increased flatus, decreased or increased passage of stool, stool 
consistency, urgency and feeling of incomplete evacuation5. This same questionnaire also 
included any adverse events that occurred during the study while taking the treatment. The 
patients were also required to fill out a questionnaire that rated 6 different IBS symptoms and 
rated a general assessment of health and quality of life on a visual analogue scale (VAS)5. The 
patients were asked to complete this questionnaire every night before going to sleep for the first 
week, then weekly for the duration of the study5.  The patient’s scores on the VAS scale were 
converted to a number between 0 and 105.  The symptoms that were included on the patient’s 
questionnaire were abdominal pain, intestinal gas or bloating, constipation, diarrhea, incomplete 
evacuation and urgency. 
 Cappello et. al assessed reduction of symptoms using symptom score that measured 
intensity and frequency of symptoms.  Intensity of symptoms were measured on a scale from 0 to 
4; with 0 being absent symptoms, 1 being mild, 2 being moderate, 3 being severe and 4 being 
unbearable symptoms6.  Frequency of symptoms were also measured on a scale of  0 to 4; with 0 
being absent, 1 being once per month, 2 being once per week, 3 being twice per week and 4 
being more than 3 times per week6.  The symptom scores were assessed at the beginning of the 
trial, the end of the trial and 4 weeks after the end of the trial6.  The symptoms that were 
evaluated using the symptom score were abdominal bloating or distention, abdominal pain or 
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discomfort, diarrhea (> 3 stool/day), constipation (<3 stools/week), pain at evacuation, urgency 
of bowel movement, sense of incomplete evacuation and passage of gas or mucous6.  A total IBS 
symptom score was then evaluation for each subject, by calculating the mean symptom score for 
each symptom, and then adding up the mean symptom scores for all the symptoms for each 
patient and getting the average for that6.  Any subject with a ≥50% reduction in overall IBS 
symptom score from baseline to either at the end of treatment or 4 weeks after treatment was 
defined as Remission of IBS symptoms6.  Remission of symptoms was how the study defined a 
reduction in IBS symptoms for these patients. 
 Alam et. al assessed the changes in symptoms using a symptom score, which was 
assessed before treatment as a baseline, and at 3 week intervals during the treatment and then 2 
weeks after the end of treatment4.  Quality of life was assessed using a validated IBS quality of 
life instrument, which included 34 questionnaires for the patients to fill out4.  Quality of life was 
assessed before and after treatment4.  Three articles were chosen for this systematic review.  
Table 1 represents the demographics and characteristics of each study that was selected. 
Table 1 - Demographics & Characteristics of included studies 
Study Type # Pts 
Age 
(yrs.) 
Inclusion 
Criteria Exclusion Criteria W/D Interventions 
Merat5 
(2010) 
Randomized 
Control Trial 
60 36 Adult patients 
with the 
diagnosis of 
Irritable bowel 
syndrome using 
Rome II criteria 
Patients with any 
abnormal results, pt.'s 
with serum markers 
for Celiac Disease, or 
other diseases such as 
lactose intolerance 
and others. 
30 Enteric-
coated 
peppermint-
oil 
(Colpermin) 
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Cappello6 
(2007) 
Randomized 
double-blind 
Control Trial 
57 41 Patients 
diagnosed with 
irritable bowel 
syndrome 
according to the 
Rome II criteria 
with no other 
abdominal 
diseases or 
abnormal 
diagnostic tests 
Patients under 18 
years old and over 80 
years old; pt.'s with 
previous surgery on 
abdomen except 
appendectomy;  pt.'s 
with other diseases of 
the abdomen 
6 Peppermint 
oil (Mintoil®) 
Alam4 
(2013) 
Randomized 
double-blind 
controlled 
trial 
74 28.74 Patients with 
diarrhea-
predominant IBS 
who fulfilled 
ROME II criteria 
Patient who had red 
flag signs such as 
weight loss, 
dysphagia, 
dehydration, 
bleeding, recurrent 
vomiting, fever, etc.  
Pregnant and 
breastfeeding women.  
Patient who had 
concomitant cardiac 
disease, liver disease, 
renal disease 
9 Peppermint 
oil 
 
Results 
 There were three randomized, double-blind, placebo controlled trials selected for this 
systematic review to determine the efficacy and safety of peppermint oil for the treatment of 
symptoms of IBS in adults.  The Merat, et. al study used dichotomous data, but was unable to 
base this on an intention-to-treat analysis.  The Cappello, et. al study used dichotomous data 
based on the intention-to-treat analysis of data.  The data presented in Alam et. al, study was 
continuous, and couldn’t be converted into dichotomous data4.  The analysis of measured 
outcomes for each of the studies is based on overall improvement of symptoms, and 
improvement in quality of life.   
 In the Merat et. al study, 90 patients overall were included in this study based on the 
inclusion and exclusion criteria, and 60 were able to complete the study with 30 lost to follow-up 
(Table 1).  This left 33 patients in the peppermint oil group and 27 patients to the placebo group.  
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The patients that participated in the study received 187 mg (or 0.2 ml) of peppermint oil 
(Colpermin) three times a day 30 minutes before each meal for 8 weeks5.  The placebo group 
received an identical looking placebo with the same regimen5.  The most common presenting 
complaints in the beginning of the study was abdominal pain, followed by distention and 
flatulence.  Quality of life was evaluated during follow-up at 1 week and then again at 4 weeks.  
Reduction of symptoms was evaluated every day during the first week and then weekly 
throughout the rest of the study.  The intensity of the abdominal pain and discomfort was 
significantly reduced in the colpermin group at week 8 compared to the placebo (p < 0.001) 
(Table 2).  Quality of life did not differ significantly at the beginning of the trial.  However, after 
8 weeks, the patients on Colpermin showed statistically significant improvement in quality of life 
according to the SF-6 domains compared to the placebo group (Table 3).  Thirty-three patients 
reported adverse events including heartburn during the study, 19 in the Colpermin group and 14 
in the placebo group.   
Table 2: Frequency and Intensity of Symptoms Abdominal pain and Discomfort at 0 and 8 
Weeks of Treatment5 
Frequency and intensity of Symptoms Study group Week 0 Week 4 Week 8 
None PG 0 11 (41%) 6 (22%) 
CG 0 14 (42%) 14 (42%) 
Occasional PG 17 (63%) 10 (37%) 7 (26%) 
CG 15 (46%) 11 (33%) 14 (42%) 
Persistent PG 9 (33%) 6 (22%) 14 (52%) 
CG 14 (42%) 7 (21%) 5 (15%) 
Severe PG 1 (4%) 0 0 
CG 4 (12%) 1 (3%) 0 
PG= Placebo group, CG= Colpermin (peppermint oil) group 
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Table 3: Mean SF-6 Score in the Beginning and the End of Treatment5 
Study group Mean SF- 6 score beginning of 
trial (SD) 
Mean SF- 6 score end of 
trial (SD) 
p-value  
Placebo Group 48.9 (29.8) 57.8 (29.3) 0.308 
Colpermin Group 53.7 (26.4) 63.0 (28.2) 0.194 
 
 Based on the results of the study, the control event rate (CER), which included the 
placebo group was 77.7%, whereas the experimental event rate (EER), which included the 
peppermint oil group was 57.6%.  The Relative Benefit Increase (RBI) was 0.26, and Absolute 
Benefit Increase (ABI) was 0.2.  Based on these calculations, the numbers needed to treat for this 
study was determined to be 5.  Meaning that for every 5 people with IBS that are treated with 
peppermint oil, 1 more patient will have relief from their symptoms compared to the placebo at 8 
weeks.   
The calculations for harm were based on the adverse events.  The CER for harm was 
11%, whereas the EER for harm was 9%.  The Relative risk Increase (RRI) for harm was 0.18, 
and Absolute risk Increase (ARI) was 0.02.  Based on these calculations, the numbers needed to 
harm for this study was determined to be 50.  Meaning that for every 50 people with IBS who are 
treated with peppermint oil, 1 more patient will have an adverse event from treatment compared 
to the placebo at 8 weeks. 
 In the Cappello et. al study, 57 patients met the inclusion and exclusion criteria, 28 were 
placed in the peppermint oil group and 29 were placed in the placebo group.  Six patients overall 
(three from each study group) were lost to follow-up, and were excluded from the study (Table 
1).  The peppermint oil group was advised to take 1 Mintoil capsule (containing 225mg of 
peppermint oil and 45 mg of Natrasorb, which is a starch that absorbs oil in solid powder) twice 
a day for 4 weeks6.  The placebo group received a capsule that contained 225mg of maltodextrin 
with mint flavor and were also advised to take one capsule twice a day for 4 weeks6.  At the end 
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of 4 weeks of treatment (T4) there was a significantly higher number of patients with a ≥ 50% 
reduction in total IBS symptoms score in the peppermint oil group than in the placebo group (p< 
0.01).  There was also a persisting beneficial effect at another subsequent 4 weeks after that in 
the peppermint oil group (p< 0.05), whereas in the placebo group, a significant number of 
patients returned to baseline (Table 4). 
Table 4: Number of patients with ≥ 50% reduction in total IBS symptom score at end of 
treatment (T4) and 4 weeks after end of treatment (T8)6 
Study Group T4 T8 
Peppermint oil 64% 46% 
Placebo group 34% 10% 
  
Based on the results in the Cappello et. al study, the CER for treatment was 10%, 
whereas the EER for treatment was 46%.  The RBI for treatment was 3.6, and ABI for treatment 
was 0.36.  Based on these calculations, the numbers needed to treat for this study was determined 
to be 3.  Meaning that for every 3 people with IBS who are treated with peppermint oil, 1 more 
patient will have relief from their symptoms compared to the placebo at 4 weeks. 
 In the Alam et. al study, 74 patients were enrolled to participate in the study, and 9 
patients dropped out of the study.  Thirty-three patients were in the peppermint oil group and 
thirty two patients were in the placebo group (Table 1).  Before treatment, there was no statistical 
difference of mean abdominal pain score between the peppermint oil group and the placebo 
group (p< 0.05).  At six weeks of treatment, the mean pain score significantly improved in the 
peppermint oil group (p>0.001), and was significant over the placebo group (p> 0.05).  Two 
weeks after the end of treatment, pain score increased in both groups (Table 5).  Quality of life 
did not improve significantly during this study.   
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Table 5: Mean symptom score throughout the study (baseline, 3 weeks, 6 weeks and 2 weeks 
after treatment), and mean overall symptom score of both study groups4 
  Mean Symptom Score Mean 
overall 
score 
  
Study group Baseline  3 weeks 6 weeks 2 weeks after 
treatment 
p-value 
Peppermint oil 6.7 6.58 4.94 6.09 4.94 > 0.0001 
Placebo 6.67 6.44 6.15 6.38 6.15 > 0.05 
 
Based on the results in the Alam et. al study, the 95% Confidence Interval (CI) for the 
experimental group was 3.75-5.53.  The 95% CI for the control group was 5.65-6.65.  This 
means there is a 95% chance that the groups are different, not by chance.  This is significant for 
this study showing the results that are significantly different, not by chance, and makes the 
results valid.  The estimate of treatment affect was fairly precise with p> 0.0001. 
Discussion 
 This systematic review compares three randomized, double blind, placebo controlled 
clinical trials, and all of them found that peppermint oil is effective at reducing the symptoms of 
IBS4, 5, 6.  Merat, et. al found significant improvement of abdominal pain and discomfort, and 
found some improvement in quality of life5.  Cappello, et. al found significant improvement in 
symptoms of IBS in patients after 4 weeks of treatment, and found continued improvement in 
symptoms after the treatment6.  Alam, et. al specifically found improvement in abdominal pain 
and diarrhea symptoms in diarrhea-predominant IBS4.   
Peppermint is a plant that belongs to the mint family that is a cross between two types of 
mint, water mint and spearmint5, 7.  Today, peppermint oil is used as a folk or traditional remedy 
for various symptoms including nausea, indigestion, cold symptoms and headaches7.  Peppermint 
oil appears to be safe for most adults when used in small doses, with possible side effects 
including allergic reactions and heartburn7. 
Farnell, Peppermint Oil and IBS 11 
 
Merat, et. al mentioned a significant limitation to their study was the number of 
participants who were lost to follow-up5. Almost 30% of their subjects did not refer for follow-
up, which made them unable to do an intention-to-treat analysis5. Another significant limitation 
to their study was the researcher and patient questionnaires were not validated5.  They were not 
concerned by this because they used the SF-6 questionnaire for analysis, and the results of the 
SF-6 questionnaire matched the results of the invalidated researcher and patient questionnaires5.  
Cappello, et. al found a significant limitation to their study was the short length of time of the 
study, and short follow-up on the patients.  They suggested that in future studies therapeutic 
periods will be required before the establishment of definite impact of peppermint oil for IBS6.  
The limitation in the Alam, et. al study was the sample size and the duration of the treatment4.  
They suggested that in future studies, larger placebo controlled trials for a longer period of 
treatment are warranted for further evaluation of peppermint oil to reduce symptoms of IBS4. 
Conclusion 
Based on these three randomized, double-blind, and placebo controlled clinical trials the 
efficacy of peppermint oil treatment to reduce symptoms of IBS is fairly conclusive4, 5, 6.  The 
results for effectiveness in improving quality of life were inconclusive.  All three randomized, 
double-blind, placebo controlled trials found a statistically significant improvement of symptoms 
of IBS, including abdominal pain, bloating and diarrhea, using peppermint oil for treatment4, 5, 6.   
In future studies, it would be useful to use larger sample sizes, and conduct the study for 
a longer period of time.  The larger sample size and longer study observation would show a more 
accurate depiction of peppermint oil’s effect on the patient population.  This would further 
ensure the validity of peppermint oil’s effectiveness at relieving symptoms and improving 
quality of life.  
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